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ABSTRACT
Introduction: Antimicrobial prescribing in the
emergency department is predominantly
empiric, with final microbiology results either
unavailable or reported after most patients are
discharged home. Systematic follow-up processes
are needed to ensure appropriate antimicrobial
therapy at this transition of care. The objective of
this study was to assess the impact of a culture
follow-up (CFU) program on the frequency of
emergency department (ED) revisits within 72 h
and hospital admissions within30 dayscompared
to the historical standard of care (SOC).
Additionally, infection characteristics and
antimicrobial therapy were compared.
Methods: A single group, pre-test post-test
quasi-experimental study was conducted
comparing a retrospective SOC group to a
prospective CFU group. CFU was implemented
using computerized decision-support software
and a multidisciplinary team of pharmacists
and emergency physician staff.
Results: Over the four-month intervention
period the CFU group evaluated 197 cultures
and modified antimicrobial therapy in 25.5%.
The rate of combined ED revisits within 72 h
and hospital admissions within 30 days was
16.9% in the SOC group and 10.2% in the CFU
group (p = 0.079). When evaluating the
uninsured population alone, revisits to the ED
within 72 h were reduced from 15.3% in the
SOC group to 2.4% in the CFU group
(p = 0.044).
These findings were presented in part as an abstract at
the 52nd ICAAC in San Francisco, September 2012.
Electronic supplementary material The online
version of this article (doi:10.1007/s40121-014-0026-x)
contains supplementary material, which is available to
authorized users.
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Conclusion: Implementation of a
multidisciplinary CFU program was associated
with a reduction in ED revisits within 72 h and
hospital admissions within 30 days. One-fourth
of patients required post-discharge
intervention, representing a large need for
antimicrobial stewardship expansion to ED
practice models.
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follow-up; Emergency department; Infectious
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INTRODUCTION
The increasing emergence of antimicrobial
resistance in both the community and
inpatient settings has become an alarming
public health concern. Infections caused by
resistant organisms have been shown to
increase morbidity, mortality, and healthcare
costs [1]. The emergence of antimicrobial
resistance has been linked to the overuse and
inappropriate prescribing of antimicrobial
therapy [2, 3]. Because it serves as a link in
transitions of care, the emergency department
(ED) represents an important target for
interventions aimed at decreasing
inappropriate antimicrobial use, especially in
the outpatient setting. ED’s across the United
States are estimated to treat over 100 million
patients annually, with approximately 15.7% of
patients discharged home with a prescription
for an antimicrobial agent [4–7]. In the ED
setting, many patients are discharged home
prior to culture and susceptibility results
becoming final. It has been reported that 5.6%
of patients discharged from the ED receive an
inappropriate medication at discharge [4].
While institution-specific empiric therapy
guidelines can help to align therapy with
national guidelines and institutional-specific
antibiogram data, pathogens are not always
susceptible to empiric therapy choices.
Prescribing of inappropriate antimicrobials
puts patients at risk for clinical failure and
subsequent revisit to the ED and readmission to
the hospital [8, 9]. Therefore, further process
improvements such as structured culture
follow-up programs must be considered to
improve antimicrobial use in the ED setting.
Cosgrove and colleagues recently published
a call to action for antimicrobial stewardship in
the ED, highlighting the importance of
judicious antimicrobial use and also the
important opportunity for antimicrobial
stewardship collaboration [10]. ED clinicians
play a prominent role in antimicrobial
stewardship; not only are they tasked with
choosing an appropriate antimicrobial regimen
but also sending indicated cultures and
performing follow-up. Pharmacists also play a
prominent role in antimicrobial stewardship
programs (ASPs) within hospitals and health
systems due to their knowledge of antimicrobial
activity, dosing, and drug interactions [11–13].
Several institutions have described their
experience with antimicrobial stewardship in
the emergency department [14–17]; however,
the optimal targets for intervention in this
setting have not been established.
The authors implemented a
multidisciplinary culture follow-up (CFU)
program in October 2011 with the purpose of
expediting the identification of patients
discharged from the ED with bacteremia and
improving the quality of urinary tract infection
management at the transition of care from ED
to home. The authors hypothesized that the
multidisciplinary culture-follow-up program
would be associated with a reduction in ED
revisits and hospitalizations.
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METHODS
Study Design and Setting
This study was conducted at an 802-bed
teaching hospital in Detroit, Michigan, with
an existing ASP presence in inpatient and ED
services. The authors conducted a single
pre-test, post-test quasi-experimental study
comparing the standard of care (SOC) to a
multidisciplinary (CFU) program. The CFU
program was implemented primarily by a
pharmacy practice resident (PGY1), with
support and oversight from the infectious
diseases and ED pharmacy specialists.
Compliance with Ethics
The study was approved by the Henry Ford
Health System Institutional Review Board and
all procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. The requirement for informed
consent was waived.
Selection of Participants
Patients were included who were 18 years of age
or older, presented to the main campus ED,
were discharged to home from the ED, and had
a blood or urine culture taken which yielded a
positive result. For patients with multiple ED
visits meeting these criteria, the first visit was
included in the study population. Patients in
both arms were identified using an electronic
screening tool in the hospital’s computerized
decision support software program (TheradocTM
Hospira, Salt Lake City, UT, USA). Patients were
excluded if they were less than 18 years of age,
presented to a satellite ED, were admitted for
inpatient treatment, or were discharged to
hospice care. Consecutive adult patients
presenting to the ED between January 1 and
April 30, 2011 and meeting the inclusion
criteria were retrospectively reviewed for
inclusion into the SOC control group.
Consecutive patients presenting to the ED
between November 7, 2011 and February 6,
2012 were prospectively identified and reviewed
for inclusion in the CFU group. Patients from
the total population were considered to have a
symptomatic urinary tract infection if they had
a positive urine culture and concurrent urinary
symptoms (excluding dysuria, frequency, or
flank pain) or bacteriuria in pregnancy.
Intervention
Prior to the CFU program, the SOC for CFU
consisted of prescriber-dependent follow-up.
Each prescriber was responsible for performing
culture follow-up for any patient whom they
saw and discharged directly home from the ED.
During both study phases, the microbiology
laboratory called the responsible ED physician
with critical values for positive blood culture
Gram stain results.
In the CFU program, computerized decision
support software alerted the CFU pharmacist to
any new positive urine or blood culture results
Monday through Friday. On weekends, CFU was
performed at the discretion of the ED prescribers
without additional pharmacist intervention.
During weekdays, the CFU pharmacist
screened the patients’ medical record for
inclusion criteria, ED and discharge
antimicrobial therapy, and other patient
characteristics. Patient characteristics evaluated
included antibiotic allergies, pregnancy status,
insurance status, serum creatinine, creatinine
clearance, and diagnostic criteria for
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symptomatic urinary tract infection. Among
patients with symptomatic urinary tract
infection or bacteriuria in pregnancy,
appropriateness of antimicrobial therapy was
defined by the pharmacist according to the
following: drug selection according to
institutional ASP guideline and susceptibility,
drug selection and dose appropriate for patient
characteristics, and duration at least the
minimum recommended. If a therapeutic
change was determined necessary, the CFU
pharmacist created a patient-specific report
including the patient’s name, contact
information, culture data, and the
recommended therapy. Categorization of
inappropriate therapy was confirmed with the
ED physician through discussion of this patient-
specific report. The pharmacist and ED
physician then determined the plan for follow-
up. The physician was responsible for contacting
the patient by telephone to assess the patient’s
symptoms and communicate whether a new
prescription was needed or if the patient should
return to the ED for treatment. In the event that
a patient was unable to be contacted via
telephone, a letter was mailed to the address
on record or another contact method was used.
Intervention was not performed in the CFU
group for patients deemed to have
asymptomatic bacteriuria (unless in pregnancy).
Data Collection
For all patients in the study population, data
were extracted from electronic medical records
by trained investigators using a standardized
case report form. Data collected included
patient demographics, infection and
microbiological characteristics, empiric
antimicrobial therapy, ED revisit within 72 h,
and hospital admission within 30 days. Time to
appropriate therapy was recorded in days and
calculated as the day from initial ED discharge
to the day that the ED physician made their first
follow-up contact attempt with the patient. The
primary endpoint for analysis was a composite
of patient revisit to the ED within 72 h of index
ED discharge or admission to the hospital
within 30 days of index ED discharge. A revisit
to the ED was defined as any unplanned
presentation for the same condition within
72 h of initial discharge [18, 19].
Analysis
The study was powered to detect a 12%
reduction in ED revisit or hospital admission
per patient compared to the previous standard
of care using a two-sided test with a significance
of 0.05 and 80% power [15]. The authors
calculated that 139 patients per phase would
need to be included in this study (n = 276
patients total). Based on the findings of Rynn
and colleagues [16] the authors anticipated that
25% of patients would require therapeutic
modification.
For all study endpoints as well as patient and
infection characteristics, categorical data were
compared using Chi square or Fisher’s exact
test; continuous data were compared using
Student’s t or Mann–Whitney U tests, as
appropriate for the distribution of the data.
Characteristics found to be associated with the
outcome in bivariate tests with a p\0.2 and
clinical rationale were considered for inclusion
in a multivariable logistic regression model. The
primary population for analysis was the total
number of cultures; subgroup analyses were
conducted for each culture site as specified a
priori. Post-hoc subgroup analysis according to
insurance status was also performed. A p\0.05
was considered significant for all comparisons.
Statistical analysis was completed using SPSS
19.0 (IBM, Inc., Armonk, NY, USA).
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RESULTS
Characteristics of Study Subjects
A total of 320 patients with 321 cultures were
included in the final analysis. Over the four-
month intervention period 651 cultures were
screened and 197 met inclusion criteria for the
CFU group. In the four-month retrospective
SOC group, 324 cultures were screened and 124
were included for comparison. Cultures were
excluded from analysis based on patient age or
hospice status, because the patient was
admitted to the hospital for treatment, or
because the culture was taken at a satellite ED.
The overwhelming majority of patients in both
groups had positive urine cultures (307 out of
321). Patient characteristics are displayed in
Table 1; patients in the SOC group were more
likely to be uninsured compared to the CFU
group [59 (47.6%) vs. 41 (20.8%) p\0.01].
Infection and Treatment Characteristics
Of the 307 urine cultures included, 100% of
patients in both the SOC and the CFU group
had a urinalysis sample taken at baseline.
In the SOC group 73.3% of patients had
documentation of symptomatic urinary tract
infection while 74.9% of the CFU group were
symptomatic (p = 0.764). Escherichia coli was the
most commonly identified urinary pathogen
in both groups. In the SOC group,
sulfamethoxazole-trimethoprim (TMP-SMX)
was the most often prescribed agent for
empiric treatment, followed by ciprofloxacin
and cephalexin. In the CFU group,
ciprofloxacin was the most commonly
prescribed agent for empiric treatment,
followed by nitrofurantoin and TMP-SMX. The
average length of empiric therapy was 8.45 days
in the SOC group and 7.59 days in the CFU
group.






Age (mean ± SD) 45.4 ± 20.6 48.2 ± 22.2 0.539
Female, n (%) 95 (76.6) 147 (74.6) 0.743
Race, n (%) 0.164
African American 95 (76.6) 155 (78.7)
Other 29 (23.4) 41 (20.8)
Pregnancy status
% females, n (%) 22 (23.2) 29 (19.7) 0.669
Uninsured patients, n (%) 59 (47.6) 41 (20.8) \0.01
Culture type (%) 0.424
Urine 120 (96.8) 187 (94.9)
Blood 4 (3.2) 10 (5.1)
CFU culture follow-up, SD standard deviation
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A total of 14 blood cultures were included in
the final analysis, 4 in the SOC group and 10 in
CFU. Streptococcal species were the most
common organisms identified in blood
followed by Enterobacteriaceae; there were no
Staphylococcus aureus blood stream infections in
the study population. Only one patient in the
CFU group required follow-up; the other nine
cultures received adequate follow-up based on
their initial gram stain report, prior to the
pharmacist reviewing their cultures.
Outcomes
Empiric therapy was considered appropriate for
63.1% of the SOC cultures and 73% of CFU
cultures (p = 0.081). Modification of antibiotic
therapy was needed in 25.5% of the cases
screened in the CFU group. The most common
reason for intervention was pathogen non-
susceptibility (38/50, 76%), followed by dose
adjustments (5/50, 10%), increasing duration of
therapy (4/50, 8%), and admission to the
hospital for intravenous therapy (2/50, 4%). Of
the 50 patients requiring intervention, the
median time to follow-up and receipt of
appropriate therapy was 2 days (interquartile
range 2–3 days). Follow-up contact was made by
telephone (87.5%), letter (8.9%), or through
communication with the patients’ primary care
physician (3.6%).
The combined primary endpoint of ED
revisit within 72 h or hospital admission
within 30 days was 16.9% in the SOC group
and 10.2% in the CFU group (p = 0.079) (see
Table 2) Of the 21 patients having either an ED
revisit or hospital admission in the SOC group,
76.2% returned due to an infection-related
issue, while 55% of the 20 patients admitted
in the CFU group returned for an infection-
related issue (p = 0.153). In the subset of
patients without medical insurance, 59 in the
SOC group and 41 in the CFU group, the 72-h
revisits to the ED were significantly reduced
from 15.3% in the SOC group to 2.4% in the
CFU group (p = 0.044). There was no difference
in the incidence of hospital admissions at
30 days in this subset.
The subset of patients with urinary tract
infections were evaluated further to determine
the effect of various factors on the combined
endpoint. Covariates found to be associated with
the outcome in bivariate analyses included study
group (OR = 0.53, p = 0.073), presence of dysuria
at baseline (OR = 0.36, p = 0.022), and presence
of urinary frequency at baseline (OR = 0.39,
p = 0.054). Insurance status was not associated
with the outcome (OR = 0.67, p = 0.25), nor was
adequate empiric therapy (OR = 0.54,
p = 0.092). In restricted multivariable logistic
regression, presence of dysuria and frequency
were combined into one variable (v2 = 69.817,
p\0.001). After controlling for the presence of
dysuria or frequency, the intervention reduced
revisit and admission (adjusted OR = 0.477, 95%
CI 0.234–0.973, p = 0.042).
Table 2 Combined primary endpoint and components
SOC group (n5 124) CFU group (n5 197) p value
ED revisit within 72 h, n (%) 12 (9.7) 12 (6.1) 0.239
Hospital admission within 30 days, n (%) 13 (10.5) 14 (7.1) 0.295
Combined ED revisit within 72 h and hospital
admission within 30 days, n (%)
21 (16.9) 20 (10.2) 0.079
CFU culture follow-up, ED emergency department, SOC standard of care
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DISCUSSION
This study has found that implementation of a
multidisciplinary CFU program resulted in an
approximately 7% decrease in combined ED
revisits within 72 h and hospital admissions at
30 days when compared to a non-standardized
follow-up method. While this finding was
statistically significant only in the multivariate
analysis, this program improved quality of
antimicrobial utilization and follow-up.
Interestingly, the subgroup analysis in the
uninsured population suggests that this
intervention could have a dramatic impact in
populations with limited access to care.
Other characteristics found to be associated
with improved outcome were documented
urinary frequency and dysuria; the authors
speculate that this may be related to improved
awareness and aggressive antimicrobial therapy
among ED providers responding to these well-
defined symptoms of urinary tract infections. In
addition, the authors noted a numerical
increase in appropriate empiric therapy and a
significant increase in the use of nitrofurantoin
in the CFU group, corresponding to a change in
national and institutional recommendations for
cystitis [20]. Despite this, intervention by the
multidisciplinary CFU providers was still
necessary in 25.5% of cases, and the most
common reason for intervention was pathogen
non-susceptibility. This is similar to reports
from antimicrobial stewardship programs in
other EDs with intervention rates ranging
from 15 to 25% [15, 16]. This variance may be
due in part to the population that each
institution chooses to target. Whilst the
authors limited their intervention to urine and
blood cultures, others have also included
sexually transmitted diseases, skin and skin
structure infection, and respiratory tract
infections.
There are potential limitations to this study
that must be considered. The multidisciplinary
CFU was only available for culture follow-up
Monday–Friday. During weekend shifts,
prescribers were instructed to continue culture
follow-up with their same pre-intervention
method; in nearly all cases this resulted in
delaying intervention until the pharmacist
initiated follow-up on Monday. Another
limitation was reliance on electronic physician
documentation to confirm if the patient was
reached for changes in therapy. Calculating the
time to appropriate therapy was, therefore,
based on the day the physician contacted the
patient. Limitations may also exist due to the
quasi-experimental design, including potential
bias in the assessment of empiric appropriate
treatment, the lack of study group
randomization, and potential for regression
toward the mean in the post-intervention
group [21]. A quasi-experimental design was
selected for the study because withholding
multidisciplinary follow-up from randomly
selected patients would be impractical and
potentially unethical. Last, while the authors
believe the decrease in ED revisits and hospital
admissions was significant to their institution,
this study did not achieve the effect size for
which it was designed, possibly due to the
numerical increase in appropriate empiric
therapy also seen after implementation of the
CFU group when compared to the SOC. The
impact of this study may have been greater with
the inclusion of follow-up for sexually
transmitted diseases (STDs) and other sites of
bacterial culture.
CONCLUSION
Over a 4-month period, a multidisciplinary
culture follow-up program in the ED was
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effective in improving the quality of care, but
did not achieve a statistical reduction in ED
revisit and hospital admission compared to
standard of care. Interventions targeting
infection management in high-risk ED patients
may show an even greater impact.
Antimicrobial stewardship interventions at the
transition of care were required in one-fourth of
patients, supporting the need for continued
expansion of antimicrobial stewardship services
in the ED.
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